Hutchmed to showcase targeted oncology pipeline and surufatinib data at AACR
Hutchmed (NASDAQ:HCM) announced on April 9, 2026, that it will present a series of new preclinical and clinical datasets at the American Association for Cancer Research (AACR) Annual Meeting.










